Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base

iScience 2026 Open access

Read full text
Authors: Masayuki Aboshi, Daisuke Kawakami, Kaoru Kono, Ayae Nishiyama, Takuto Nogimori, Yuko Sunada, Kenta Matsuda, Takashi Sekida, Shigeru Suga, Jonathan Smith, Nobuaki Sato, Takuya Yamamoto
+1 more Wataru Akahata
DOI: 10.1016/j.isci.2026.114766
Cited by: 2
References: 12

Abstract

T cell responses. These results indicate that the incorporation of a modified 5 mC base improves the safety profile of the saRNA vaccine without compromising immunogenicity, supporting further development of this platform as a booster vaccine.

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research Immune responses and vaccinations Immunotherapy and Immune Responses

Publication details

Journal / source
iScience
Publisher
Elsevier BV
Volume
29
Issue
2
Pages
114766–114766
Publication date
22 January 2026
Language
EN